论文部分内容阅读
选择冠心病稳定型心绞痛病人２６例，口服维拉帕米１８０ｍｇ／日２周，采用竞争性酶联免疫法测定血小板膜糖蛋白Ⅱｂ／Ⅲａ（ＧＰⅡｂ／Ⅲａ）受体分子数并分析其服药前后变化与血小板功能变化关系。结果显示：服药２周后血小板ＧＰⅡｂ／Ⅲａ．分子数明显减少（３９１９６±３４１７对８２４８７±５２８和４７８６１±４７９６对４０７４９±２５６２分子数／血小板，Ｐ＜０．００５和Ｐ＜０．００１）．二者均与血小板粘附率变化差值呈良好相关（Ｐ＜０．００１）。本研究说明口服常规剂量的维拉帕米能降低血小板膜ＧＰⅡｂ／Ⅲａ。受体分子数，具有抑制血小板功能作用。
26 patients with stable angina pectoris of coronary heart disease and 180 mg / day of verapamil were orally administered for two weeks. The number of platelet glycoprotein Ⅱb / Ⅲa (GPⅡb / Ⅲa) receptor molecules was measured by competitive enzyme-linked immunosorbent assay before and after administration Relationship between changes and platelet function changes. The results showed: platelet GPⅡb / Ⅲa after 2 weeks. The number of molecules was significantly reduced (39196 ± 3417 versus 82487 ± 528 and 47861 ± 4796 versus 40749 ± 2562 molecules / platelet, P <0.005 and P <0.001). Both had a good correlation with the difference of platelet adhesion rate (P <0.001). This study shows that oral administration of conventional doses of verapamil can reduce platelet membrane GP Ⅱ b / Ⅲ a. Receptor molecules, with the role of inhibiting platelet function.